Drug Resistance Outpaces Pharma Innovation

The article begins by emphasising the severity of the problem that AMR poses to public health, noting the “widening gap between the escalating global health threat of antimicrobial resistance (AMR) and the pharmaceutical industry's innovation efforts.”

The article mentions the seven promising late-stage identified for new medicines targeting infectious pathogens identified in the report, noting that companies like India-based Aurobindo Pharma are recognised for paediatric formulations, yet access gaps remain, especially in sub-Saharan Africa.

It also mentions industry recommendations from the report, including the creation of diverse partnerships and novel payment models to advance progress on AMR.